Biohaven Shoots For Oral CGRP Leadership As Nurtec ODT Gains Momentum

The firm’s acute migraine treatment Nurtec ODT generated $65m in 2020 after launching a year ago. Biohaven aims for Nurtec to become the leader in what could be a $4bn-$5bn category in the US.

airport runway under the sun as background
Biohaven says Nurtec ODT launch is off to a strong start • Source: Shutterstock

Biohaven Pharmaceutical Holding Company Ltd. believes Nurtec ODT (rimegepant) is poised to become the market-leading oral calcitonin gene-related peptide (CGRP) antagonist on the market after a successful early launch in the midst of the COVID-19 pandemic. Nurtec ODT generated $65m in 2020, reflecting about nine months of sales after the drug launched that March, the company reported on 1 March.

The launch exceeded management's expectations with around 337,000 prescriptions written for Nurtec OTD in 2020 by 24,000 unique prescribers.

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip